← Back to Search

Other

Efficacy and Safety of ALT-801 in the Treatment of Obesity

Phase 2
Waitlist Available
Research Sponsored by Altimmune, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years

Summary

This trial is testing a medication called ALT-801 to help people who are obese or overweight lose weight when combined with diet and exercise.

Eligible Conditions
  • Obesity/Overweight

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Side effects data

From 2016 Phase 1 & 2 trial • 68 Patients • NCT01326871
100%
Platelet count decreased
100%
Nausea
100%
Vomiting
100%
Neutrophil count decreased
100%
Pruritus
100%
Rash maculo-papular
67%
Pyrexia
67%
Fatigue
67%
Constipation
67%
White blood cell count decreased
67%
Anaemia
67%
Dry skin
33%
Pain
33%
Aspartate aminotransferase increased
33%
Blood alkaline phosphatase increased
33%
Chills
33%
Oedema peripheral
33%
Influenza like illness
33%
Dyspepsia
33%
Alanine aminotransferase increased
33%
Weight increased
33%
Hyponatraemia
33%
Hypophosphataemia
33%
Lymphocyte count decreased
33%
Decreased appetite
33%
Hypoalbuminaemia
33%
Hypocalcaemia
33%
Alopecia
33%
Cough
33%
Rhinitis allergic
33%
Headache
33%
Hypotension
33%
Skin infection
33%
Cystitis
33%
Fall
33%
Contusion
33%
Vision blurred
100%
80%
60%
40%
20%
0%
Study treatment Arm
ALT-801 0.04 mg/kg With Cisplatin and Gemcitabine
ALT-801 0.06 mg/kg With Cisplatin and Gemcitabine
ALT-801 0.06 mg/kg With Gemcitabine

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: ALT-801 Dose Level 3Experimental Treatment1 Intervention
Group II: ALT-801 Dose Level 2Experimental Treatment1 Intervention
Group III: ALT-801 Dose Level 1Experimental Treatment1 Intervention
Group IV: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ALT-801
2010
Completed Phase 2
~840

Find a Location

Who is running the clinical trial?

Altimmune, Inc.Lead Sponsor
16 Previous Clinical Trials
1,154 Total Patients Enrolled
Sarah K Browne, MDStudy DirectorAltimmune, Inc.
2 Previous Clinical Trials
159 Total Patients Enrolled
~107 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top